Non-responders to treatment with antagonists of vascular endothelial growth factor in age-related macular degeneration
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
PURPOSE: Most of the publications on modern therapy of neovascular age-related macular degeneration focus on the effect of the treatment. The purpose of this study is to determine the frequency of non-responders to anti-vascular endothelial growth factor (anti-VEGF) treatment and find possible reasons for their failure to respond. METHODS: The records of patients treated until the end of 2008 the first time with either bevacizumab or ranibizumab were reviewed. Based on the availability of measurable results and according to prior publications showing the effect of the therapy, loss of three lines of distance acuity, increase of retinal thickness or lesion size were identified as indicators of non-responders. Two of these three signs had to be present. RESULTS: 334 eyes of 283 patients were included; 74.55% received bevacizumab and 25.45% received ranibizumab. Overall 14.37% of the eyes were identified as non-responders (14.06% in the bevacizumab group and 15.29% in the ranibizumab group). Baseline distance acuity and vitreo-retinal adhesions were significantly correlated with non-responders. Correlations with age, gender, lesion type, other morphologic features, and the kind of anti-VEGF agent failed to be significant. 10.4% of the non-responders showed a delayed but good response to anti-VEGF treatment. CONCLUSIONS: About 15% did not sufficiently respond to anti-VEGF treatment. Vitreo-retinal adherences were the only ophthalmologic factor which could be identified to be significantly correlated with insufficient response.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ranibizumab for Neovascular Age-Related Macular Degeneration
Rosenfeld, P. J., Brown, D. M., Heier, J. S., Boyer, D. S., Kaiser, P. K., Chung, C. Y., & Kim, R. Y. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054481 · Cited by 5,886
Ranibizumab and bevacizumab for neovascular age-related macular degeneration
(2011) · New England Journal of Medicine · doi:10.1056/nejmoa1102673 · Cited by 2,669
Kaiser, P. K., Brown, D. M., Zhang, K., Hudson, H. L., Holz, F. G., Shapiro, H., Schneider, S., & Acharya, N. R. (2007) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2007.08.012 · Cited by 361
Cohen, S. Y., Oubraham, H., Uzzan, J., Dubois, L., & Tadayoni, R. (2012) · Retina · doi:10.1097/iae.0b013e318240a516 · Cited by 61
Cited by
Defining response to anti-VEGF therapies in neovascular AMD
Amoaku, W. M., Chakravarthy, U., Gale, R., Gavin, M., Ghanchi, F., Gibson, J., Harding, S., Johnston, R. L., Kelly, S., Lotery, A., et al. (2015) · Eye · doi:10.1038/eye.2015.48 · Cited by 355
Gyenes, A., István, L., Benyó, F., Papp, A., Resch, M., Sándor, N., Józsi, M., Nagy, Z. Z., Kovács, I., & Kiss, S. (2023) · BMC Ophthalmology · doi:10.1186/s12886-022-02761-9 · Cited by 9
Han, J. W., Yang, J. Y., Kim, Y., An, S., Yoo, E., Park, I. H., Lee, S.-W., Lee, H.-J., Lee, T. G., Jung, W. H., et al. (2026) · Molecular Therapy: Nucleic Acids · doi:10.1016/j.omtn.2026.103101 · Cited by 1
Metadata
- Authors
- Krebs, I., Glittenberg, C., Ansari-Shahrezaei, S., Hagen, S., Steiner, I., & Binder, S.
- Venue
- British Journal of Ophthalmology
- Publisher
- BMJ
- Published
- 2013-08-21
- Volume
- 97
- Issue
- 11
- Pages
- 1443-1446
- ISSN
- 0007-1161 (ISSN-L)
- 1468-2079
- OpenAlex
- W2102167881
- Cited by
- 123
- References
- 4
- FWCI
- 9.04
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Non-responders to treatment with antagonists of vascular endothelial growth factor in age-related macular degeneration. https://app.cochat.ai/papers/10.1136/bjophthalmol-2013-303513
- The paper
- Krebs, I., Glittenberg, C., Ansari-Shahrezaei, S., Hagen, S., Steiner, I., & Binder, S. (2013). Non-responders to treatment with antagonists of vascular endothelial growth factor in age-related macular degeneration. British Journal of Ophthalmology. https://doi.org/10.1136/bjophthalmol-2013-303513
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.